Lilly China Drug Development

Lilly China Drug Development Center (LCDDC), based in Shanghai, is a critical hub within Eli Lilly and Company's global research and development network. The center is dedicated to accelerating the clinical development and regulatory approval of Lilly's innovative pipeline for the Chinese market, focusing on therapeutic areas such as oncology, diabetes, immunology, and neurodegeneration. LCDDC is well-known for its strategic "In China, For Global" and "In China, For China" strategies, which involve deep collaborations with local biotechnology leaders like Innovent Biologics and Hutchmed. By leveraging local clinical data and expertise, the center ensures that breakthrough therapies reach Chinese patients in tandem with global launches. Its operations span the entire development lifecycle, from early-phase clinical trials to comprehensive post-market surveillance.